Copyright
©The Author(s) 2017.
World J Gastrointest Oncol. Jul 15, 2017; 9(7): 281-292
Published online Jul 15, 2017. doi: 10.4251/wjgo.v9.i7.281
Published online Jul 15, 2017. doi: 10.4251/wjgo.v9.i7.281
Adjuvant systemic therapy | |||||||||
Study[20,22-24,26,27,29] | Treatment | Treatment group | Control group | ||||||
DFS (mo) | OS (mo) | 2 yr survival | 5 yr survival | DFS (mo) | OS (mo) | 2 yr survival | 5 yr survival | ||
5-FU based treatments | |||||||||
ESPAC-1 Neoptolemos et al[20], 2001 | 5-FU/LV vs observation | - | 19.7 | - | - | - | 14.0 | - | - |
ESPAC-1 and 3 pooled analysis Neoptolemos et al[22], 2009 | 5-FU/LV vs observation | - | 23.2 | 49.0% | 24.0% | - | 16.8 | 37.0% | 14.0% |
Gemcitabine based treatments | |||||||||
CONKO-001, Oettle et al[24], 2007 | Gemcitabine vs observation | 13.4 | 22.1 | - | 16.5% | 6.9 | 20.5 | - | 5.5% |
JSAP-02, Ueno et al[26], 2009 | Gemcitabine vs observation | 11.4 | 22.3 | 48.3% | 23.9% | 5.0 | 18.4 | 40.0% | 10.6% |
Gemcitabine compared to 5-FU | |||||||||
ESPAC-3, Neoptolemos et al[23], 2010 | Gemcitabine vs 5-FU/LV | 14.3 | 23.6 | 29.6% | - | 14.1 | 23.0 | 30.7% | - |
RTOG 97-04, Regine et al[27], 2008 | Gemcitabine vs 5-FU/LV in patients receiving CRT | - | 20.5 | - | - | - | 16.9 | - | - |
Combination treatments | |||||||||
ESPAC-4, Neoptolemos et al[29], 2017 | Gemcitabine plus capecitabine vs Gemcitabine | 13.9 | 28.0 | 53.8% | - | 13.1 | 25.5 | 52.1% | - |
First line treatment for metastatic disease | |||||||||
Study[41,49,63-67,71] | Treatment | Treatment group | Control group | ||||||
ORR | PFS (mo) | OS (mo) | 1 yr Survival | ORR | PFS (mo) | OS (mo) | 1 yr Survival | ||
Standard of care | |||||||||
Burris et al[41], 1997 | Gemcitabine vs 5-FU/LV | - | 9 wk | 5.65 | 18.0% | - | 4 wk | 4.01 | 2.0% |
Conroy et al[49], 2011 | FOLFIRINOX vs Gemcitabine | 31.6% | 6.4 | 11.1 | 48.4% | 9.4% | 3.3 | 6.8 | 20.6% |
Von Hoff et al[71], 2013 | Nab-paclitaxel plus gemcitabine vs gemcitabine | 23.0% | 5.5 | 8.5 | 35.0% | 7.0% | 3.7 | 6.7 | 22.0% |
Gemcitabine doublets | |||||||||
Berlin et al[63], 2002 | Gemcitabine plus 5-FU vs gemcitabine | 6.9% | 3.4 | 6.7 | - | 5.6% | 2.2 | 5.4 | - |
Herrmann et al[64], 2007 | Gemcitabine plus capecitabine vs gemcitabine | 10.0% | 4.3 | 8.4 | 32.0% | 7.8% | 3.9 | 7.2 | 30.0% |
Moore et al[66], 2007 | Gemcitabine plus erlotinib vs gemcitabine | 8.6% | 3.8 | 6.2 | 23.0% | 8.0% | 3.6 | 5.9 | 17.0% |
Philip et al[67], 2010 | Gemcitabine plus cetuximab vs gemcitabine | 12.0% | 3.4 | 6.3 | - | 14.0% | 3.0 | 5.9 | - |
Ueno et al[65], 2013 | Gemcitabine plus S1 vs gemcitabine | 29.3% | 5.7 | 10.1 | 40.7% | 13.3% | 4.1 | 8.8 | 35.4% |
- Citation: Lau SC, Cheung WY. Evolving treatment landscape for early and advanced pancreatic cancer. World J Gastrointest Oncol 2017; 9(7): 281-292
- URL: https://www.wjgnet.com/1948-5204/full/v9/i7/281.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v9.i7.281